null
ChEBI ID: 26338
| Member | Definition | Role |
|---|---|---|
| 13,14-dihydro-15-ketoprostaglandin e1 | A prostaglandin E obtained by formal oxidation of the 15-hydroxy group and hydrogenation of the 13,14-double bond of prostaglandin E1. | 13,14-dihydro-15-oxoprostaglandin E1 |
| 15-keto-13,14-dihydroprostaglandin e2 | The 13,14-dihydro derivative of 15-oxo-prostaglandin E2. | 13,14-dihydro-15-oxo-prostaglandin E2 |
| 15-ketoprostaglandin e | 15-dehydro-prostaglandin E1 | |
| 15-ketoprostaglandin e2 | 15-dehydro-prostaglandin E2 | |
| 6-ketoprostaglandin e1 | A prostaglandin E that is prostaglandin E1 bearing a keto substituent at the 6-position. | 6-oxoprostaglandin E1 |
| alprostadil | prostaglandin E1 | |
| dinoprostone | Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins. | prostaglandin E2 |
| prostaglandin e3 | prostaglandin E3 |
| Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
|---|---|---|
| pre-1990 | 8,090 (23.79) | 18.7374 |
| 1990's | 9,798 (28.81) | 18.2507 |
| 2000's | 8,327 (24.49) | 29.6817 |
| 2010's | 6,464 (19.01) | 24.3611 |
| 2020's | 1,325 (3.90) | 2.80 |
| Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
|---|---|---|
| Trials | 2,229 (6.09%) | 5.53% |
| Reviews | 1,636 (4.47%) | 6.00% |
| Case Studies | 635 (1.74%) | 4.05% |
| Observational | 35 (0.10%) | 0.25% |
| Other | 32,043 (87.60%) | 84.16% |